Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pre-treatment metastatic biopsy : a step towards precision oncology for urothelial cancer

Klümper, Niklas ; Cox, Alexander ; Sjödahl, Gottfrid LU ; Roghmann, Florian ; Bolenz, Christian ; Hartmann, Arndt ; Grünwald, Viktor ; Faltas, Bishoy M. ; Hölzel, Michael and Eckstein, Markus (2024) In Nature Reviews Urology
Abstract

Early metastatic spread and clonal expansion of individual mutations result in a heterogeneous tumour landscape in metastatic urothelial cancer (mUC). Substantial molecular heterogeneity of common drug targets, such as membranous NECTIN4, FGFR3 mutations, PDL1 or immune phenotypes, has been documented between primary and metastatic tumours. However, translational and clinical studies frequently do not account for such heterogeneity and often investigate primary tumour samples that might not be representative in patients with mUC. We propose this as a potential factor for why many biomarkers for mUC have failed to be integrated into clinical practice. Fresh pre-treatment metastatic biopsies enable the capturing of prevailing tumour... (More)

Early metastatic spread and clonal expansion of individual mutations result in a heterogeneous tumour landscape in metastatic urothelial cancer (mUC). Substantial molecular heterogeneity of common drug targets, such as membranous NECTIN4, FGFR3 mutations, PDL1 or immune phenotypes, has been documented between primary and metastatic tumours. However, translational and clinical studies frequently do not account for such heterogeneity and often investigate primary tumour samples that might not be representative in patients with mUC. We propose this as a potential factor for why many biomarkers for mUC have failed to be integrated into clinical practice. Fresh pre-treatment metastatic biopsies enable the capturing of prevailing tumour biology in real time. The characterization of metastatic tumour samples can improve response prediction to immunotherapy, the anti-NECTIN4 antibody–drug conjugate enfortumab vedotin and the FGFR inhibitor erdafitinib. Routine metastatic biopsy can thus improve the precision of identifying driver druggable alterations, thus improving treatment selection for patients with mUC.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Nature Reviews Urology
publisher
Nature Publishing Group
external identifiers
  • pmid:39472646
  • scopus:85207891071
ISSN
1759-4812
DOI
10.1038/s41585-024-00951-2
language
English
LU publication?
yes
id
df749ffb-7afa-4d64-b8f3-91fc784ba76e
date added to LUP
2024-12-11 13:24:04
date last changed
2025-07-24 21:12:22
@article{df749ffb-7afa-4d64-b8f3-91fc784ba76e,
  abstract     = {{<p>Early metastatic spread and clonal expansion of individual mutations result in a heterogeneous tumour landscape in metastatic urothelial cancer (mUC). Substantial molecular heterogeneity of common drug targets, such as membranous NECTIN4, FGFR3 mutations, PDL1 or immune phenotypes, has been documented between primary and metastatic tumours. However, translational and clinical studies frequently do not account for such heterogeneity and often investigate primary tumour samples that might not be representative in patients with mUC. We propose this as a potential factor for why many biomarkers for mUC have failed to be integrated into clinical practice. Fresh pre-treatment metastatic biopsies enable the capturing of prevailing tumour biology in real time. The characterization of metastatic tumour samples can improve response prediction to immunotherapy, the anti-NECTIN4 antibody–drug conjugate enfortumab vedotin and the FGFR inhibitor erdafitinib. Routine metastatic biopsy can thus improve the precision of identifying driver druggable alterations, thus improving treatment selection for patients with mUC.</p>}},
  author       = {{Klümper, Niklas and Cox, Alexander and Sjödahl, Gottfrid and Roghmann, Florian and Bolenz, Christian and Hartmann, Arndt and Grünwald, Viktor and Faltas, Bishoy M. and Hölzel, Michael and Eckstein, Markus}},
  issn         = {{1759-4812}},
  language     = {{eng}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Nature Reviews Urology}},
  title        = {{Pre-treatment metastatic biopsy : a step towards precision oncology for urothelial cancer}},
  url          = {{http://dx.doi.org/10.1038/s41585-024-00951-2}},
  doi          = {{10.1038/s41585-024-00951-2}},
  year         = {{2024}},
}